Last reviewed · How we verify
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; (GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;) — Yongtao Sun.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; TARGET | GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; | Yongtao Sun | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; CI watch — RSS
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; CI watch — Atom
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; CI watch — JSON
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; alone — RSS
Cite this brief
Drug Landscape (2026). GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; — Competitive Intelligence Brief. https://druglandscape.com/ci/groupb-liposomal-bupivacaine-and-bupivacaine-hydrochloride. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab